天津医药

天津医药 ›› 2015, Vol. 43 ›› Issue (10): 1156-1158.doi: 10.11958/j.issn.0253-9896.2015.10.019

• 临床研究 • 上一篇    下一篇

鼠神经生长因子治疗前部缺血性视神经病变疗效观察

  

  1. 天津中医药大学第一附属医院 （邮编300193）
  • 收稿日期:2015-04-28 修回日期:2015-06-22 出版日期:2015-10-15 发布日期:2015-10-22

Clinical observation of the effect of mouse nerve growth factor on anterior ischemic optic#br# neuropathy

  1. First Hospital Affiliated to Tianjin University of Chinese Medicine, Tianjin 300193, China
  • Received:2015-04-28 Revised:2015-06-22 Published:2015-10-15 Online:2015-10-22

PDF (PC)

4104

摘要：

摘要： 目的 观察鼠神经生长因子（NGF）治疗前部缺血性视神经病变（AION）的临床疗效。方法 将 78 例
AION 患者随机分为鼠 NGF 治疗组 （治疗组） 39 例 （39 眼） 和常规治疗组 （对照组） 37 例 （37 眼）。对照组爱维治 1.2 g
静脉滴注， 1 次/d， 治疗组加用肌内注射鼠 NGF 18 μg， 1 次/d， 两组同时给予甲钴胺片口服 0.5 mg， 3 次/d， 并根据发病
时间长短及视盘水肿情况给予地塞米松注射液 3 mg 球后注射 1 次/d， 3～5 d。14 d 为 1 个疗程， 治疗 28 d 后观察疗
效。结果 治疗组， 显效 28 眼 （71.79%）， 有效 7 眼 （17.95%）， 无效 4 眼 （10.26%）， 总有效率 89.74%； 对照组， 显效 11
眼（29.73%）， 有效 15 眼（40.54%）， 无效 11 眼（29.73%）， 总有效率 70.27%。2 组疗效差异有统计学意义（Z=3.552，
P＜0.05）。治疗后治疗组视力及视野平均光敏感度均好于对照组， 差异有统计学意义 （P＜0.05）。结论 鼠 NGF 治
疗 AION 能有效提高视力， 改善视野， 临床效果明显， 值得推广。

关键词: 缺血, 视神经疾病, 神经生长因子类, 鼠科, 注射剂, 治疗

Abstract:

Abstract： Objective To observe curative effect of the rat nerve growth factor (NGF) treatment on anterior ischemic op⁃
tic neuropathy（AION） . Methods Patients with AION (n=78) were randomly divided into mouse NGF treatment group
(treatment group): 39 cases (39 eyes) and conventional treatment group (control group): 37 cases (37 eyes). Patients in control
group were given Actovegin 1.2 g intravenously, once a day while patients in treatment group were given 18 μg mouse NGF
once a day. Milton insurable were given orally at 0.5 mg, 3 times per day at both groups. Dexamethasone of 3 mg were given
retrobulbarly once a day upon onset of symptoms and the extend of edema for 3 to 5 days. Rat nerve growth factor were given
for consecutive14 days as a period of treatment, and the curative effect was observed after 28 days of treatment. Results In
the treatment group: treatments were obviously effective in 28 eyes (71.79%), effective in 7 eyes (17.95%) and ineffective in
4 eyes (10.26%), so the total effective rate was 89.74%; In control group: treatments were obviously effective in 11 eyes
(29.73%), effective in 15 eyes (40.54%) and ineffective in 11 eyes (29.73%), so the total effective rate was 70.27%. Curative
effects in these 2 groups were of statistical significance (Z=3.552, P＜0.05). Vision acuity and average light sensitivity in vi⁃
sual field are better in treatment group than those control group (P＜0.05). Conclusion Mouse NGF is effective in the treat⁃
ment of AION and can improve vision acuity and visual field, therefore is worth promoting

Key words: ischemia, optic nerve diseases, nerve growth factors, muridae, injectio, therapy